What is Zembrace® SymTouch®

Zembrace® SymTouch® is a prescription medicine used to treat acute migraine headaches with or without aura in adults 18 years of age and older who have been diagnosed with migraine.

Zembrace® SymTouch® should not be used to treat other types of headaches such as hemiplegic (that make you unable to move on one side of your body) or basilar (rare form of migraine with aura) migraines.

Zembrace® SymTouch® is not used to prevent or decrease the number of migraines you have.

See Important Safety Information for other reasons you should not use Zembrace® Symtouch®.

Fast and powerful

In as little as 10 minutes, you may get migraine relief (17% for sumatriptan 3 mg vs. 5% for placebo). One study showed that 60% of people experienced pain relief within 2 hours of use (vs. 21% for placebo).1

The most common side effects of Zembrace® SymTouch® include pain and redness at your injection site; tingling or numbness in your fingers or toes; dizziness; warm, hot burning feeling to your face (flushing); discomfort or stiffness in your neck; feeling weak, drowsy or tired.1

Simple

  • Smallest needle in a sumatriptan pen3 (auto-injector)
  • Simple, two-step injection process1,4
  • No refrigeration needed*

Zembrace® SymTouch® for as little as $0*

Eligible commercially ensured patients may pay as little as $0* per prescription, per month with free home delivery through Blink Pharmacy Plus.

Fast, free home delivery

Fast, free home delivery only through Blink Pharmacy Plus.

Get Savings

*Restrictions and quantity limits apply.  Click to view complete program terms and conditions. Medicare, Medicaid, and other federal and state healthcare program patients are not eligible.

Instructions for Use

Learn how to use the Zembrace® SymTouch® pen.

Watch video

Download Instructions for Use

References:

  1. Zembrace SymTouch [package insert]. Maple Grove, MN: Upsher-Smith Laboratories, LLC: July 2019.
  2. Mathew NT, et al. Dose ranging efficacy and safety of subcutaneous sumatriptan in the acute treatment of migraine. US Sumatriptan Research Group. Arch Neurol. 1992;49(12):1271-1276.
  3. Data on file. Maple Grove, MN: Upsher-Smith Laboratories, LLC: 2019.
  4. Brand-Schieber E, Munjal S, Kumar R, et al. Human factors validation study of 3 mg sumatriptan autoinjector, for migraine patients. Med Devices (Auckl). 2016;9:131-137.